thalidomide has been researched along with Glomerulonephritis, Membranoproliferative in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Glomerulonephritis, Membranoproliferative: Chronic glomerulonephritis characterized histologically by proliferation of MESANGIAL CELLS, increase in the MESANGIAL EXTRACELLULAR MATRIX, and a thickening of the glomerular capillary walls. This may appear as a primary disorder or secondary to other diseases including infections and autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Various subtypes are classified by their abnormal ultrastructures and immune deposits. Hypocomplementemia is a characteristic feature of all types of MPGN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 5.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| "Considering the involvement of IL-6 in Castleman's disease we treated the patient with thalidomide obtaining the remission of the nephrotic syndrome." | 1.32 | Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease. ( Canelles, MF; Menegato, MA; Pizzolitto, S; Tonutti, E, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, S | 1 |
| Bernardes, C | 1 |
| Borges, V | 1 |
| Ramos, G | 1 |
| Gorse, A | 1 |
| Boileau, J | 1 |
| Goetz, J | 1 |
| Stoll-Keller, F | 1 |
| Martin, T | 1 |
| Menegato, MA | 1 |
| Canelles, MF | 1 |
| Tonutti, E | 1 |
| Pizzolitto, S | 1 |
3 other studies available for thalidomide and Glomerulonephritis, Membranoproliferative
| Article | Year |
|---|---|
Gastric antral vascular ectasia (GAVE) and hereditary hemorrhagic telangiectasia (HHT): two different conditions, one treatment.
Topics: Angiogenesis Inhibitors; Argon Plasma Coagulation; Bevacizumab; Combined Modality Therapy; Erythrocy | 2020 |
Parvovirus B19-induced type II mixed cryoglobulinemia.
Topics: Acute Disease; Antibodies, Viral; Antineoplastic Agents; Cryoglobulinemia; Diagnosis, Differential; | 2011 |
Remission of nephrotic syndrome after thalidomide therapy in a patient with Castleman's disease.
Topics: Aged; Biopsy; Castleman Disease; Female; Glomerulonephritis, Membranoproliferative; Humans; Immunosu | 2004 |